α3 integrin-binding peptide-functionalized polymersomes loaded with volasertib for dually-targeted molecular therapy for ovarian cancer
出版年份 2021 全文链接
标题
α3 integrin-binding peptide-functionalized polymersomes loaded with volasertib for dually-targeted molecular therapy for ovarian cancer
作者
关键词
PLK1 inhibitor, Targeted delivery, Polymersomes, Targeted therapy, Ovarian cancer
出版物
Acta Biomaterialia
Volume -, Issue -, Pages -
出版商
Elsevier BV
发表日期
2021-02-07
DOI
10.1016/j.actbio.2021.02.007
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Novel monoclonal antibody against integrin α3 shows therapeutic potential for ovarian cancer
- (2020) Feng‐Yi Ke et al. CANCER SCIENCE
- GE11 peptide-installed chimaeric polymersomes tailor-made for high-efficiency EGFR-targeted protein therapy of orthotopic hepatocellular carcinoma
- (2020) Cheng Zhou et al. Acta Biomaterialia
- Actively targeted nanomedicines for precision cancer therapy: Concept, construction, challenges and clinical translation
- (2020) Wenxing Gu et al. JOURNAL OF CONTROLLED RELEASE
- Nanoparticles in precision medicine for ovarian cancer: From chemotherapy to immunotherapy
- (2020) Yuan Li et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- ROS-Responsive Polymeric Micelles for Triggered Simultaneous Delivery of PLK1 Inhibitor/miR-34a and Effective Synergistic Therapy in Pancreatic Cancer
- (2019) Xiaofei Xin et al. ACS Applied Materials & Interfaces
- Blocking Mitotic Exit of Ovarian Cancer Cells by Pharmaceutical Inhibition of the Anaphase-Promoting Complex Reduces Chromosomal Instability
- (2019) Monika Raab et al. NEOPLASIA
- Ligand density on nanoparticles: A parameter with critical impact on nanomedicine
- (2019) Alaaldin M. Alkilany et al. ADVANCED DRUG DELIVERY REVIEWS
- CD44‐Specific A6 Short Peptide Boosts Targetability and Anticancer Efficacy of Polymersomal Epirubicin to Orthotopic Human Multiple Myeloma
- (2019) Wenxing Gu et al. ADVANCED MATERIALS
- The emergence of drug resistance to targeted therapies: Clinical evidence
- (2019) Ana Bela Sarmento-Ribeiro et al. DRUG RESISTANCE UPDATES
- Gene/paclitaxel co-delivering nanocarriers prepared by framework-induced self-assembly for the inhibition of highly drug-resistant tumors
- (2019) Chenglong Wang et al. Acta Biomaterialia
- Sensitization to oxidative stress and G2/M cell cycle arrest by histone deacetylase inhibition in hepatocellular carcinoma cells
- (2019) Hae-Ahm Lee et al. FREE RADICAL BIOLOGY AND MEDICINE
- Ovarian cancer statistics, 2018
- (2018) Lindsey A. Torre et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Impact of iASPP on chemoresistance through PLK1 and autophagy in ovarian clear cell carcinoma
- (2018) Ka-Kui Chan et al. INTERNATIONAL JOURNAL OF CANCER
- Targeting the tumour stroma to improve cancer therapy
- (2018) Kenneth C. Valkenburg et al. Nature Reviews Clinical Oncology
- Synthetic lethality in CCNE1-amplified high grade serous ovarian cancer through combined inhibition of polo-like kinase 1 and microtubule dynamics
- (2018) Sabrina Noack et al. Oncotarget
- Therapeutic enhancement of a cytotoxic agent using Photochemical internalisation in 3D compressed collagen constructs of ovarian cancer
- (2018) Layla Mohammad Hadi et al. Acta Biomaterialia
- Epigenetics in ovarian cancer: premise, properties, and perspectives
- (2018) Qilian Yang et al. Molecular Cancer
- HDAC Inhibition Counteracts Metastatic Re-Activation of Prostate Cancer Cells Induced by Chronic mTOR Suppression
- (2018) Jasmina Makarević et al. Cells
- Boosting RNAi therapy for orthotopic glioblastoma with nontoxic brain-targeting chimaeric polymersomes
- (2018) Yanan Shi et al. JOURNAL OF CONTROLLED RELEASE
- Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
- (2018) Kathleen Moore et al. NEW ENGLAND JOURNAL OF MEDICINE
- PLK1, A Potential Target for Cancer Therapy
- (2017) Zhixian Liu et al. Translational Oncology
- Co-delivery of Se nanoparticles and pooled SiRNAs for overcoming drug resistance mediated by P-glycoprotein and class III β-tubulin in drug-resistant breast cancers
- (2016) Wenjing Zheng et al. Acta Biomaterialia
- Novel mechanisms and approaches to overcome multidrug resistance in the treatment of ovarian cancer
- (2016) Fang Ren et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- Overcoming ABC transporter-mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug strategies
- (2016) Wen Li et al. DRUG RESISTANCE UPDATES
- Volasertib Versus Chemotherapy in Platinum-Resistant or -Refractory Ovarian Cancer: A Randomized Phase II Groupe des Investigateurs Nationaux pour l'Etude des Cancers de l'Ovaire Study
- (2016) Eric Pujade-Lauraine et al. JOURNAL OF CLINICAL ONCOLOGY
- Precision targeted therapy of ovarian cancer
- (2016) Justin Sapiezynski et al. JOURNAL OF CONTROLLED RELEASE
- Spotlight on Volasertib: Preclinical and Clinical Evaluation of a Promising Plk1 Inhibitor
- (2016) J. Van den Bossche et al. MEDICINAL RESEARCH REVIEWS
- Plk1 Inhibitors in Cancer Therapy: From Laboratory to Clinics
- (2016) Rosie Elizabeth Ann Gutteridge et al. MOLECULAR CANCER THERAPEUTICS
- Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer
- (2016) Angela George et al. Nature Reviews Clinical Oncology
- Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells
- (2016) Michael Ramirez et al. Nature Communications
- Ovarian cancer
- (2016) Ursula A. Matulonis et al. Nature Reviews Disease Primers
- Reduced Efficacy of the Plk1 Inhibitor BI 2536 on the Progression of Hepatocellular Carcinoma due to Low Intratumoral Drug Levels
- (2015) Jörg Haupenthal et al. NEOPLASIA
- Combined mTOR inhibitor rapamycin and doxorubicin-loaded cyclic octapeptide modified liposomes for targeting integrin α3 in triple-negative breast cancer
- (2014) Wenbing Dai et al. BIOMATERIALS
- Ovarian cancer
- (2014) Gordon C Jayson et al. LANCET
- Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy
- (2014) B T Gjertsen et al. LEUKEMIA
- Polypeptide-based combination of paclitaxel and cisplatin for enhanced chemotherapy efficacy and reduced side-effects
- (2013) Wantong Song et al. Acta Biomaterialia
- "OA02" Peptide Facilitates the Precise Targeting of Paclitaxel-Loaded Micellar Nanoparticles to Ovarian Cancer In Vivo
- (2012) K. Xiao et al. CANCER RESEARCH
- Effect of ligand density, receptor density, and nanoparticle size on cell targeting
- (2012) Drew R. Elias et al. Nanomedicine-Nanotechnology Biology and Medicine
- A combinatorial extracellular matrix platform identifies cell-extracellular matrix interactions that correlate with metastasis
- (2012) Nathan E. Reticker-Flynn et al. Nature Communications
- Exploiting the Cancer Genome: Strategies for the Discovery and Clinical Development of Targeted Molecular Therapeutics
- (2011) Timothy A. Yap et al. Annual Review of Pharmacology and Toxicology
- Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress
- (2011) Twan Lammers et al. JOURNAL OF CONTROLLED RELEASE
- WWOX Gene Expression Abolishes Ovarian Cancer Tumorigenicity In vivo and Decreases Attachment to Fibronectin via Integrin 3
- (2009) C. Gourley et al. CANCER RESEARCH
- BI 6727, A Polo-like Kinase Inhibitor with Improved Pharmacokinetic Profile and Broad Antitumor Activity
- (2009) D. Rudolph et al. CLINICAL CANCER RESEARCH
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started